CAR-T boxed warnings: What comes next?
The FDA recently asked the six marketed CAR-T therapies to add a new boxed warning item on their labels to reflect the risk of secondary T-cell cancers. This decision follows an investigation into the new safety signal from postmarketing adverse event reports and clinical trials.
In today’s episode, Fierce Pharma’s Angus Liu talks with regulatory experts Mwango Kashoki, M.D., and Steve Winitsky, M.D., to understand the rationale behind the FDA’s decision and to discuss its implications for CAR-T candidates and their developers down the line.
Related Insights
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
CTB Blog
Expanding the promise of CAGTs through community-based care
May 8, 2026
CTB Blog
FDA’s new biosimilar guidance explained: Key changes in reference product requirements
Mar 19, 2026
CTB Blog
Harmonizing UK and EU CTA submissions: Practical strategies from EU-CTR experience
Mar 19, 2026
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026
CTB Blog
New EU pharmaceutical legislation: Strategic implications for drug developers
Feb 17, 2026
CTB Blog
EU Biotech Act: Strategic considerations for biotech companies
Dec 22, 2025
Related Insights
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
CTB Blog
Expanding the promise of CAGTs through community-based care
May 8, 2026
CTB Blog
FDA’s new biosimilar guidance explained: Key changes in reference product requirements
Mar 19, 2026
CTB Blog
Harmonizing UK and EU CTA submissions: Practical strategies from EU-CTR experience
Mar 19, 2026
CTB Blog
Decoding FDA's new ‘plausible mechanism framework’ guidance: what drug developers need to know
Feb 27, 2026